Clinical Trial Update: NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients

View source ↗

Summary

Completed real-world study evaluating the effectiveness of the Budesonide/Formoterol/Glycopyrronium fixed-triple inhaler (NEXThaleR) on COPD symptom scores.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide/Formoterol/Glycopyrronium (BDP/FF/G) (budesonide/formoterol/glycopyrronium)

Snippet

Sponsor: Chiesi Hungary Ltd. | Conditions: COPD | Status: COMPLETED